Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity

Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity

Abstract Background Stereotactic ablative radiotherapy (SABR) offers an alternative treatment for pancreatic cancer, with the potential for improved tumour control and reduced toxicity compared with conventional therapies. However, optimal dose planning and delivery strategies are unelucidated and g...

Full description

Bibliographic Details
Main Authors: Christy Goldsmith, P. Nicholas Plowman, Melanie M. Green, Roger G. Dale, Patricia M. Price
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Radiation Oncology
Subjects:
Stereotactic ablative radiotherapy (SABR)
Cyberknife®
Pancreatic cancer
Radiobiology
Dose escalation
Local control
Online Access:http://link.springer.com/article/10.1186/s13014-018-1138-3

Internet

http://link.springer.com/article/10.1186/s13014-018-1138-3

Similar Items